BR112012004983A2 - anticorpos humanizados específicos para métodos de pepetídeo-6 derivado de hsp65 - Google Patents
anticorpos humanizados específicos para métodos de pepetídeo-6 derivado de hsp65 Download PDFInfo
- Publication number
- BR112012004983A2 BR112012004983A2 BR112012004983-6A BR112012004983A BR112012004983A2 BR 112012004983 A2 BR112012004983 A2 BR 112012004983A2 BR 112012004983 A BR112012004983 A BR 112012004983A BR 112012004983 A2 BR112012004983 A2 BR 112012004983A2
- Authority
- BR
- Brazil
- Prior art keywords
- ser
- tyr
- leu
- gly
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1289—Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24021809P | 2009-09-06 | 2009-09-06 | |
| US61/240,218 | 2009-09-06 | ||
| PCT/IL2010/000731 WO2011027349A1 (en) | 2009-09-06 | 2010-09-06 | Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012004983A2 true BR112012004983A2 (pt) | 2021-02-23 |
Family
ID=43648941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012004983-6A BR112012004983A2 (pt) | 2009-09-06 | 2010-09-06 | anticorpos humanizados específicos para métodos de pepetídeo-6 derivado de hsp65 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8680241B2 (https=) |
| EP (2) | EP2475383A4 (https=) |
| JP (1) | JP5781514B2 (https=) |
| KR (1) | KR101831229B1 (https=) |
| CN (1) | CN102740877B (https=) |
| AU (1) | AU2010290844B2 (https=) |
| BR (1) | BR112012004983A2 (https=) |
| CA (1) | CA2772567A1 (https=) |
| IN (1) | IN2012DN02869A (https=) |
| MX (1) | MX2012002768A (https=) |
| RU (1) | RU2596925C2 (https=) |
| WO (1) | WO2011027349A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE048024T2 (hu) * | 2006-08-10 | 2020-05-28 | Roy C Levitt | Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra |
| ES2857553T3 (es) * | 2014-10-24 | 2021-09-29 | Hoffmann La Roche | Humanización de anticuerpos basada en ángulo interdominio VH-VL |
| US10538561B2 (en) | 2015-01-22 | 2020-01-21 | Isanaka Ram | Peptide for treating inflammatory diseases |
| US11623950B2 (en) * | 2015-07-09 | 2023-04-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Lentiviral vector expressing membrane-anchored or secreted antibody |
| MX385370B (es) * | 2016-03-31 | 2025-03-18 | Immutrix Therapeutics Inc | Metodo para el tratamiento extracorporeo de preeclampsia y trastornos relacionados. |
| MX2021001268A (es) | 2018-08-01 | 2021-09-08 | Imcheck Therapeutics Sas | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. |
| WO2025155809A2 (en) * | 2024-01-18 | 2025-07-24 | Nextcure, Inc. | Compositions and methods for modulating vstm-1 mediated signal transduction |
| WO2025231127A1 (en) * | 2024-05-02 | 2025-11-06 | The Regents Of The University Of California | Compositions and methods for intracellular antigen targeting with antibodies |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9125979D0 (en) * | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
| US7488476B2 (en) * | 1998-11-05 | 2009-02-10 | Hadasit Medical Research Services & Development Ltd. | B-cell epitope peptides of HSP 65, DNA encoding said peptides, antibodies directed against said peptides and the different uses thereof in the treatment of inflammatory and autoimmune diseases |
| AU759303B2 (en) * | 1998-11-05 | 2003-04-10 | Hadasit Medical Research Services & Development Company Ltd | Novel amino acid sequences, DNA encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof |
| AU2002360857A1 (en) * | 2001-12-31 | 2003-07-24 | L.A.S. Trust, Ein 02/6105365 | Recreational vehicle |
| EP1619521A1 (en) | 2004-07-22 | 2006-01-25 | IEE INTERNATIONAL ELECTRONICS & ENGINEERING S.A. | Capacitive transmitter electrode |
| CU23504A1 (es) * | 2004-09-24 | 2010-04-13 | Ct Ingenieria Genetica Biotech | Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas |
| AU2006210724A1 (en) | 2005-02-03 | 2006-08-10 | Antitope Limited | Human antibodies and proteins |
| US20070048325A1 (en) * | 2005-08-24 | 2007-03-01 | Dennis Van Epps | Combination therapies for inhibiting integrin-extracellular matrix interactions |
| PL1989544T3 (pl) | 2006-03-02 | 2012-01-31 | Antitope Ltd | Testy na komórkach T |
| US20080019979A1 (en) * | 2006-05-22 | 2008-01-24 | Feng Wang-Johanning | HERV-K Antigens, Antibodies, and Methods |
| JPWO2008114733A1 (ja) | 2007-03-16 | 2010-07-01 | 協和発酵キリン株式会社 | 抗Ｃｌａｕｄｉｎ−４抗体 |
| UA104132C2 (en) | 2007-11-13 | 2014-01-10 | Тева Биофармасьютикалз Юесей, Инк. | Humanized antibodies against tl1a |
| EP2414397A1 (en) | 2009-03-30 | 2012-02-08 | Protab Ltd. | Adenylyl cyclase-associated protein (cap1) and uses thereof as a target for immuno-modulation |
| US20140170157A1 (en) * | 2011-06-15 | 2014-06-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of selecting therapeutic indications |
-
2010
- 2010-09-06 JP JP2012527448A patent/JP5781514B2/ja not_active Expired - Fee Related
- 2010-09-06 BR BR112012004983-6A patent/BR112012004983A2/pt not_active Application Discontinuation
- 2010-09-06 CA CA2772567A patent/CA2772567A1/en not_active Abandoned
- 2010-09-06 MX MX2012002768A patent/MX2012002768A/es not_active Application Discontinuation
- 2010-09-06 RU RU2012106891/10A patent/RU2596925C2/ru not_active IP Right Cessation
- 2010-09-06 KR KR1020127008389A patent/KR101831229B1/ko not_active Expired - Fee Related
- 2010-09-06 EP EP10813428.9A patent/EP2475383A4/en not_active Withdrawn
- 2010-09-06 WO PCT/IL2010/000731 patent/WO2011027349A1/en not_active Ceased
- 2010-09-06 CN CN201080050177.2A patent/CN102740877B/zh not_active Expired - Fee Related
- 2010-09-06 IN IN2869DEN2012 patent/IN2012DN02869A/en unknown
- 2010-09-06 US US13/392,548 patent/US8680241B2/en not_active Expired - Fee Related
- 2010-09-06 EP EP18161381.1A patent/EP3366308A1/en not_active Withdrawn
- 2010-09-06 AU AU2010290844A patent/AU2010290844B2/en not_active Ceased
-
2014
- 2014-01-31 US US14/169,996 patent/US20140170138A1/en not_active Abandoned
-
2017
- 2017-04-19 US US15/491,377 patent/US20170218056A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2475383A4 (en) | 2013-07-17 |
| WO2011027349A1 (en) | 2011-03-10 |
| RU2596925C2 (ru) | 2016-09-10 |
| IN2012DN02869A (https=) | 2015-07-24 |
| EP2475383A1 (en) | 2012-07-18 |
| KR20120060224A (ko) | 2012-06-11 |
| CA2772567A1 (en) | 2011-03-10 |
| JP5781514B2 (ja) | 2015-09-24 |
| AU2010290844B2 (en) | 2015-04-09 |
| CN102740877B (zh) | 2015-01-14 |
| CN102740877A (zh) | 2012-10-17 |
| JP2013503852A (ja) | 2013-02-04 |
| AU2010290844A1 (en) | 2012-03-15 |
| EP3366308A1 (en) | 2018-08-29 |
| US8680241B2 (en) | 2014-03-25 |
| US20120156201A1 (en) | 2012-06-21 |
| MX2012002768A (es) | 2012-06-28 |
| KR101831229B1 (ko) | 2018-02-22 |
| RU2012106891A (ru) | 2013-10-27 |
| US20140170138A1 (en) | 2014-06-19 |
| US20170218056A1 (en) | 2017-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012004983A2 (pt) | anticorpos humanizados específicos para métodos de pepetídeo-6 derivado de hsp65 | |
| AU738981B2 (en) | Methods and compositions for immunomodulation | |
| KR102866306B1 (ko) | 신경 성장 인자에 대한 단일 클론 항체, 및 이의 코딩 유전자 및 용도 | |
| BR112019019111A2 (pt) | anticorpo de b7-h3, seu fragmento de ligação ao antígeno e seu uso médico | |
| US20100189715A1 (en) | Humanized monoclonal antibodies that protect against shiga toxin induced disease | |
| CN112538112B (zh) | 抗α-溶血素的抗体及其应用 | |
| BR112020019647A2 (pt) | Anticorpo anti-cd27, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo | |
| Tokuda et al. | Consensus statements for medical practice: Biological agents and lung disease [Abridged English translation by the Japanese Respiratory Society] | |
| CN112125975B (zh) | Pd-l1和cd47双特异性融合蛋白及其医药用途 | |
| BR112021005169A2 (pt) | um anticorpo anti-ox40, fragmento de ligação ao antígeno do mesmo e uso farmacêutico | |
| JP7758672B2 (ja) | 抗インターロイキン－２３ ｐ１９抗体およびそれの使用方法 | |
| KR20230003187A (ko) | 인터루킨-34 표적화 화합물 및 방법 | |
| CN104817641A (zh) | 新型抗人il-23受体抗体 | |
| BR112021008424A2 (pt) | Anticorpo anti-fn14 humano | |
| CN112480259B (zh) | 抗tnfr2抗体及其用途 | |
| Hiriart et al. | Preclinical studies of NEAST (neutralizing equine anti-Shiga toxin): a potential treatment for prevention of Stec-Hus | |
| JP2018517670A (ja) | クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）感染および関連疾患の治療方法 | |
| CN114269788A (zh) | 一种能够与人4-1bb结合的分子及其应用 | |
| WO2023186113A1 (zh) | 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用 | |
| WO2012062072A1 (zh) | 抗血管抑素受体人鼠嵌合单克隆抗体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |